Dublin, Jan. 03, 2024 (GLOBE NEWSWIRE) — The “Global Natural Killer Cells Therapeutics Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” report has been added to ResearchAndMarkets.com’s offering.
The global natural killer cells therapeutics market size reached US$ 2.5 Billion in 2022. Looking forward, the market is expected to reach US$ 5.4 Billion by 2028, exhibiting a growth rate (CAGR) of 13.70% during 2022-2028.
A significant rise in the number of individuals with cancer, infectious diseases, and liver disorders represents one of the primary factors fueling the market growth. This can be attributed to unhealthy dietary patterns, lack of physical activities, growing air pollution, and the increasing number of individuals consuming alcohol and tobacco products.
Moreover, as the risk of developing cancer rises dramatically with age, the increasing geriatric population across the globe is acting as another growth-inducing factor catalyzing the demand for NK cells therapeutics. Apart from this, as the immune response of cancer patients is not adequate, health companies are developing novel methods and technologies to boost the immune response through allogeneic, off-the-shelf NK cell-based therapies.
Furthermore, there is a rise in the number of clinical studies that focus on tumor-targeted antibody strategies to enhance the therapeutic benefit of NK-cell-based therapy while minimizing risks and toxicities. In addition, governing agencies of numerous countries are funding financial schemes for cancer patients, which is creating a favorable outlook for the market.
Key Questions Answered in This Report
- What was the size of the global natural killer cells therapeutics market in 2022?
- What is the expected growth rate of the global natural killer cells therapeutics market during 2023-2028?
- What are the key factors driving the global natural killer cells therapeutics market?
- What has been the impact of COVID-19 on the global natural killer cells therapeutics market?
- What is the breakup of the global natural killer cells therapeutics market based on the therapeutics?
- What is the breakup of the global natural killer cells therapeutics market based on the application?
- What is the breakup of the global natural killer cells therapeutics market based on the end user?
- What are the key regions in the global natural killer cells therapeutics market?
- Who are the key players/companies in the global natural killer cells therapeutics market?
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 138 |
| Forecast Period | 2022 – 2028 |
| Estimated Market Value (USD) in 2022 | $2.5 Billion |
| Forecasted Market Value (USD) by 2028 | $5.4 Billion |
| Compound Annual Growth Rate | 13.7% |
| Regions Covered | Global |
Competitive Landscape
- Affimed GmbH
- Bristol-Myers Squibb Company
- Fate Therapeutics
- Fortress Biotech Inc.
- Glycostem Therapeutics
- Innate Pharma S.A.
- Kuur Therapeutics Inc. (Athenex Inc.)
- Nkarta Inc.
- Takeda Pharmaceutical Company Limited
- Ziopharm Oncology Inc.
Key Market Segmentation
Breakup by Therapeutics:
- NK Cell Therapies
- NK Cell Directed Antibodies
Breakup by Application:
- Cancer
- Gastrointestinal Diseases
- Immunoproliferative Disorders
Breakup by End User:
- Hospitals
- Research Centers and Institutes
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Latin America
- Brazil
- Mexico
- Middle East and Africa
For more information about this report visit https://www.researchandmarkets.com/r/18d90n
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Global Natural Killer Cells Therapeutics Market
